Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TXMD message board posts where the ticker symbol TXMD has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TXMD SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001387131-18-000732 (34 Act)  Size: 247 KB
2018-02-20 001-00100
18624675
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001387131-18-000665 (34 Act)  Size: 138 KB
2018-02-14 005-32384
18613852
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002414 (34 Act)  Size: 7 KB
2018-02-14 005-32384
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-001618 (34 Act)  Size: 9 KB
2018-02-13 005-32384
18600198
5  Documents Annual statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-000566 Size: 8 KB
2018-02-12
5  Documents Annual statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-000565 Size: 6 KB
2018-02-12
5  Documents Annual statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-000564 Size: 7 KB
2018-02-12
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-003875 (34 Act)  Size: 45 KB
2018-02-09 005-32384
18589647
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001390777-18-000051 (34 Act)  Size: 54 KB
2018-02-07 005-32384
18580835
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000038777-18-000031 (34 Act)  Size: 202 KB
2018-02-05 005-32384
18574223
More TXMD SEC Filings


Related news from
Tue, 20 Feb 2018
22:29:25 +0000
TherapeuticsMD reports 4Q loss
On a per-share basis, the Boca Raton, Florida-based company said it had a loss of 10 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Tue, 20 Feb 2018
21:05:00 +0000
TherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced its fourth quarter and full-year financial results for 2017.
Tue, 20 Feb 2018
17:09:35 +0000
TherapeuticsMD Q4 Earnings Preview
TherapeuticsMD (NYSE: TXMD ) will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Wall ...
Tue, 20 Feb 2018
17:00:00 +0000
TherapeuticsMD, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 20, 2018 / TherapeuticsMD, Inc. (NASDAQ: TXMD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 20, 2018 at 4:30 PM Eastern ...
Tue, 20 Feb 2018
13:06:17 +0000
See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. ETFs that hold TXMD had net inflows of $378 million over the last one-month.
Thu, 15 Feb 2018
12:45:00 +0000
Research Report Identifies Louisiana-Pacific, Vmware, ZAGG, FS Investment, TherapeuticsMD, and Kennedy-Wilson with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Louisiana-Pacific ...
Tue, 06 Feb 2018
21:30:00 +0000
TherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced that it will host a conference call and live audio webcast to discuss its fourth quarter and year end 2017 financial and business results on Tuesday, February 20.
Wed, 03 Jan 2018
21:30:00 +0000
TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced that the company will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 in San Francisco.
Fri, 29 Dec 2017
14:55:02 +0000
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
Thu, 28 Dec 2017
21:30:00 +0000
TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
TherapeuticsMD, Inc. , an innovative women’s healthcare company, announced today that it has submitted the New Drug Application for TX-001HR, the company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause, with the U.S.
Tue, 26 Dec 2017
17:16:33 +0000
ETFs with exposure to TherapeuticsMD, Inc. : December 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TherapeuticsMD, Inc. Here are 5 ETFs with the largest exposure to TXMD-US. Comparing the performance and risk of TherapeuticsMD, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Mon, 25 Dec 2017
14:37:11 +0000
TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
Categories: Yahoo FinanceGet free summary analysis TherapeuticsMD, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TherapeuticsMD, Inc. – AMAG Pharmaceuticals, Inc., Agile Therapeutics, Inc., Lannett Company, Inc., Apricus Biosciences, Inc., AbbVie, Inc., Pfizer Inc., Repros Therapeutics Inc., Juniper Pharmaceuticals, Inc. and Pernix Therapeutics Holdings, ... Read more <b>(Read more...)</b>
Wed, 20 Dec 2017
15:11:03 +0000
TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.
Wed, 20 Dec 2017
14:05:07 +0000
TherapeuticsMD shares drop 7% on new FDA review timeline for its drug
TherapeuticsMD Inc. shares dropped 7% in premarket trade on Wednesday after the company said the Food and Drug Administration will re-review its therapy by the end of May. The FDA classified the resubmission ...
Tue, 19 Dec 2017
21:36:00 +0000
TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the acceptance of the New Drug Application resubmission for TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse , a symptom of vulvar and vaginal atrophy due to menopause, by the U.S.
Fri, 01 Dec 2017
12:30:00 +0000
Recent Analysis Shows FS Investment, TherapeuticsMD, Kennedy-Wilson, Louisiana-Pacific, Vmware, and ZAGG Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS ...
Thu, 30 Nov 2017
14:42:22 +0000
Cantor Bets TherapeuticsMD Bears Could Be Getting Desperate; Here’s Why
TherapeuticsMD Inc (NASDAQ:TXMD) has a bull cheering on back of news the drug maker is resubmitting its NDA to the FDA for vaginal softgel capsule TX-004- an asset that this Wall Street analyst votes has good chances for approval, especially if regulators are involved here. Cantor analyst William Tanner finds that as the company makes its way to garnering the FDA nod in dyspareunia, what reasons do bears have left to cling to aside from "desperation?"



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is comprised of a large and growing, diverse, knowledgeable group of investors. The attribute you should appreciate that this wonderful group makes available to you as an incoming member is Generosity. Research, firsthand sector sophistication, source references and sometimes remarkably insightful analyses are given freely by the members so you may do your own due dilligence in making informed investment decisions." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards